Application of Molecular Adsorbent Recirculating System® in patients with severe liver failure after hepatic resection or transplantation:: initial single-centre experiences

被引:45
作者
Kellersmann, R [1 ]
Gassel, HJ [1 ]
Bühler, C [1 ]
Thiede, A [1 ]
Timmermann, W [1 ]
机构
[1] Univ Wurzburg, Dept Surg, D-97080 Wurzburg, Germany
来源
LIVER | 2002年 / 22卷
关键词
albumin dialysis; liver failure; liver resection; liver transplantation; MARS (R);
D O I
10.1034/j.1600-0676.2002.00011.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Acute liver failure after hepatic surgery is still plaqued with high mortality rate. Recently, a liver dialysis system (MARS(R)) that allows detoxification of albumin-bound substances and may hereby support liver regeneration and patient's recovery has been developed. In the present study, we report our experiences with MARS(R) dialysis in patients with liver failure after hepatic resection or transplantation. Between September 1999 and January 2001, five patients were treated with MARS(R) (2-5 courses). Though beneficial effects such as improvement of encephalopathy and renal function as well as reduced bilirubin levels were recorded during MARS(R) therapy, only one patient survived. Neither significant technical problems nor adverse effects occurred by using MARS(R) dialysis. We conclude that in surgical patients, acute liver failure is usually part of a complicated clinical course affecting multipleorgan systems. Thus, it is difficult to determine the specific influence of MARS(R) on patient's outcome. However, beneficial effects observed in our patients justify its continuous use and may stimulate further evaluation in controlled studies with surgical patients.
引用
收藏
页码:56 / 58
页数:3
相关论文
共 12 条
[1]  
BOZETTI F, 1992, HEPATOGASTROENTEROL, V39, P237
[2]  
Bzeizi K I, 1997, Liver Transpl Surg, V3, P137, DOI 10.1002/lt.500030206
[3]   Risk of major liver resection in patients with underlying chronic liver disease - A reappraisal [J].
Farges, O ;
Malassagne, B ;
Flejou, JF ;
Balzan, S ;
Sauvanet, A ;
Belghiti, J .
ANNALS OF SURGERY, 1999, 229 (02) :210-215
[4]  
KASAKOFF L, 2001, Z GASTROENTEROL S, V39, P50
[5]  
Loock J, 2001, Z Gastroenterol, V39 Suppl 2, P18, DOI 10.1055/s-2001-919057
[6]   Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS:: Results of a prospective, randomized, controlled clinical trial [J].
Mitzner, SR ;
Stange, J ;
Klammt, S ;
Risler, T ;
Erley, CM ;
Bader, BD ;
Berger, ED ;
Lauchart, W ;
Peszynski, P ;
Freytag, J ;
Hickstein, H ;
Loock, J ;
Löhr, JM ;
Liebe, S ;
Emmrich, J ;
Korten, G ;
Schmidt, R .
LIVER TRANSPLANTATION, 2000, 6 (03) :277-286
[7]   Use of MARS in the treatment of acute liver failure: Preliminar monocentric experience [J].
Novelli, G ;
Rossi, M ;
Pretagostini, R ;
Poli, L ;
Peritore, D ;
Berloco, P ;
Di Nicuolo, A ;
Iappelli, M ;
Cortesini, R .
TRANSPLANTATION PROCEEDINGS, 2001, 33 (1-2) :1942-1944
[8]  
SCHACHSCHAL G, 2001, 3 INT S ALB DIAL LIV
[9]  
Sechser A, 2001, Clin Liver Dis, V5, P415, DOI 10.1016/S1089-3261(05)70172-0
[10]   Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume [J].
Shirabe, K ;
Shimada, M ;
Gion, T ;
Hasegawa, H ;
Takenaka, K ;
Utsunomiya, T ;
Sugimachi, K .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1999, 188 (03) :304-309